A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase III Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
Latest Information Update: 21 Jun 2023
Price :
$35 *
At a glance
- Drugs Artesunate/pyronaridine (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Shin Poong Pharmaceutical
- 16 Jun 2023 Status changed from recruiting to completed.
- 13 Nov 2022 Planned End Date changed from 30 Nov 2022 to 30 Dec 2022.
- 13 Nov 2022 Planned primary completion date changed from 30 Oct 2022 to 30 Dec 2022.